Why the study?
Does selective class I HDAC inhibition improve pulmonary arterial pressure and cardiopulmonary remodeling in a rat model of hypoxia-induced pulmonary hypertension?
Does selective class I HDAC inhibition improve pulmonary arterial pressure and cardiopulmonary remodeling in a rat model of hypoxia-induced pulmonary hypertension?
Selective class I HDAC inhibitors demonstrate potential as novel therapeutics for pulmonary hypertension by targeting cardiopulmonary remodeling mechanisms distinct from standard vasodilators.
No takes yet. Share an insight, caveat, or question.
May support class I HDAC inhibition for experimental PH remodeling; leaves open translation to human disease.
Cavasin et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: